Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab Induction with Steroid/CNI Avoidance in Kidney Transplant
NCT00166712Phase 4Terminated
- Sponsor
- Northwestern University
- Start
- Apr 2005
- Primary completion
- Apr 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alemtuzumab in kidney transplant rejection (2 arms), sponsored by Northwestern University. Primary endpoint: Incidence of Biopsy-proven Acute Allograft Rejection at 12 months. Started Apr 2005; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00166712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166712.